These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8962201)

  • 21. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Hambach L; Eder M; Dammann E; Battmer K; Stucki A; Heil G; Ganser A; Hertenstein B
    Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.
    Wu T; Sozen H; Luo B; Heuss N; Kalscheuer H; Lan P; Sutherland DE; Hering BJ; Guo Z
    Bone Marrow Transplant; 2002 Jun; 29(12):949-56. PubMed ID: 12098061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
    Maschan AA; Trakhtman PE; Balashov DN; Shipicina IP; Skorobogatova EV; Skvortsova YV; Dyshlevaja ZM; Samochatova EV; Rumiantsev AG
    Bone Marrow Transplant; 2004 Aug; 34(4):305-7. PubMed ID: 15195080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term donor-specific tolerance in rat cardiac allografts by intrabone marrow injection of donor bone marrow cells.
    Guo K; Inaba M; Li M; An J; Cui W; Song C; Wang J; Cui Y; Sakaguchi Y; Tsuda M; Omae M; Ando Y; Li Q; Wang X; Feng W; Ikehara S
    Transplantation; 2008 Jan; 85(1):93-101. PubMed ID: 18192918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal protocol for total body irradiation for allogeneic bone marrow transplantation in mice.
    Cui YZ; Hisha H; Yang GX; Fan TX; Jin T; Li Q; Lian Z; Ikehara S
    Bone Marrow Transplant; 2002 Dec; 30(12):843-9. PubMed ID: 12476275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of mixed chimerism in mice by employing different conditioning protocols and bone marrow cell transplantation.
    Baśkiewicz-Masiuk M; Grymuła K; Hałasa M; Pius E; Boehlke M; Machaliński B
    Transplant Proc; 2009 Jun; 41(5):1894-9. PubMed ID: 19545752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.
    Yanagisawa R; Nakazawa Y; Sakashita K; Tanaka M; Shikama N; Kamijo T; Shiohara M; Koike K
    Pediatr Transplant; 2009 Sep; 13(6):737-45. PubMed ID: 19207225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
    Liu YP; Li Z; Nador RG; Strober S
    Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical roles of memory T cells and antidonor immunoglobulin in rejection of allogeneic bone marrow cells in sensitized recipient mice.
    Nagata S; Okano S; Yonemitsu Y; Nakagawa K; Tomita Y; Yoshikai Y; Shimada M; Maehara Y; Sueishi K
    Transplantation; 2006 Sep; 82(5):689-98. PubMed ID: 16969294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful allogeneic stem cell transplantation with fludarabine-based conditioning regimen in severe aplastic anemia.
    Ambulkar I; Parikh PM; Saikia T
    J Assoc Physicians India; 2003 Jul; 51():715-6. PubMed ID: 14621044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermediate TCR cells can induce graft-versus-host disease after allogeneic bone marrow transplantation.
    Weerasinghe A; Kawamura T; Moroda T; Seki S; Watanabe H; Abo T
    Cell Immunol; 1998 Apr; 185(1):14-29. PubMed ID: 9636679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: synergism with veto cells and rapamycin.
    Steiner D; Brunicki N; Bachar-Lustig E; Taylor PA; Blazar BR; Reisner Y
    Exp Hematol; 2006 Jun; 34(6):802-8. PubMed ID: 16728286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flt-3 ligand increases microchimerism but can prevent the therapeutic effect of donor bone marrow in transiently immunosuppressed cardiac allograft recipients.
    Antonysamy MA; Steptoe RJ; Khanna A; Rudert WA; Subbotin VM; Thomson AW
    J Immunol; 1998 Apr; 160(8):4106-13. PubMed ID: 9558122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of cyclosporin A on the alloreactivity of fresh and ex vivo-expanded T lymphocytes.
    Contassot E; Robinet E; Angonin R; Laithier V; Bittencourt M; Pavy JJ; Cahn JY; Hervé P; Tiberghien P
    Bone Marrow Transplant; 1998 Dec; 22(11):1097-102. PubMed ID: 9877273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prolonged chimerism of lymphoid tissue obtained in adult mice using cyclophosphamide].
    Pevnitskiĭ LA; Solov'ev VV; Fontalin LN; Andreson RK
    Biull Eksp Biol Med; 1971 Aug; 72(8):71-5. PubMed ID: 4939474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.